SignaBlok attended the COVID-19 Virtual Partnering event and presented company’s approach to treatment of acute respiratory distress syndrome (ARDS), a major complication in severe cases of COVID-19

SignaBlok > News

SignaBlok > News

SignaBlok attended the COVID-19 Virtual Partnering event and presented company’s approach to treatment of acute respiratory distress syndrome (ARDS), a major complication in severe cases of COVID-19

Inhibition of Triggering Receptor Expressed on Myeloid Cells 1 Ameliorates Inflammation and Macrophage and Neutrophil Activation in Alcoholic Liver Disease in Mice

Tornai D, Furi I et al. Hepatol Commun. 2019

SignaBlok pitched on company’s standalone and combination immuno-oncology therapy at the 2019 Life Sciences Summit

SignaBlok wins NCI / NIH SBIR Phase II grant to test first-in-class TREM-1 inhibitor in combination with chemo- and immunotherapy for treatment of pancreatic cancer

SignaBlok selected as a RESI Pitch Challenge finalist to pitch on company’s oncology program at the 2019 Redefining Early Stage Investments (RESI) Conference

Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes

Pullikuth et al. Front Oncol. 2021

Commentary: Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation

Sigalov AB. Front Immunol. 2020

Targeting Tumor-Associated Macrophages to Radiosensitize Glioblastoma in a Mouse Model

Mark DJ, Ruggieri M et al. Int J Radiat Oncol Biol Phys. 2019

SignaBlok presented data on preclinical antitumor activity of a first-in-class TREM-1 inhibitory peptide GF9 as monotherapy and in combo with chemotherapy or radiation at the 2019 AACR Annual Meeting

SignaBlok presented preclinical data supporting efficacy of ligand-independent TREM-1 inhibitor in ameliorating alcoholic liver disease at the Liver Meeting 2018: American Association for the Study of Liver Diseases (AASLD)